Clinical Trial Update: Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated adding VigantOL Oil (vitamin D3) versus placebo to Rebif in patients with relapsing-remitting multiple sclerosis; the study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)
• VigantOL Oil (vitamin D3 (cholecalciferol))

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2016-07-11